This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
VISION Trial
Treatment Considerations in the First Line Setting of mCRPC
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Centers of Excellence
Urologic Oncology
Left Group
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Clinical Trials
From the Editor
Search Clinical Trials
Transformative Trials
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
RSNA 2022
SUO 2022
Urologists for Social Responsibility 2023
Upcoming
ASCO GU 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO 2017
ASCO 2017
Prostate Cancer
Bladder Cancer
Renal Cancer
Penile Cancer
Testicular Cancer
Adrenocortical Cancer
Press Releases
ASCO 2017 Renal Cancer
Viewing 1-20 of 44 articles
ASCO 2017: Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients
ASCO 2017: Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT)
ASCO 2017: Can Subgroup Analyses Identify Enrichment Strategies for Adjuvant RCC Studies?
ASCO 2017: Emerging VEGF-I/O Combinations: Efficacy and Toxicity
ASCO 2017: A phase I/II study to assess the safety and efficacy of pazopanib and pembrolizumab in patients with advanced renal cell carcinoma
ASCO 2017: Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer
ASCO 2017: Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab in cisplatin-ineligible advanced urothelial cancer
ASCO 2017: Integrative analysis of sarcomatoid clear-cell renal cell carcinomas reveals an immune subgroup
ASCO 2017: IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma patients of atezolizumab and bevacizumab vs and following atezo or sunitinib
ASCO 2017: First-line avelumab + axitinib therapy in patients with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial
ASCO 2017: Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression
ASCO 2017: Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in patients with advanced renal cell carcinoma
ASCO 2017: TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents
ASCO 2017: A phase III study of atezolizumab vs placebo as adjuvant therapy in renal cell carcinoma patients at high risk of recurrence following resection (IMmotion010)
ASCO 2017: Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC)
ASCO 2017: A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC)
ASCO 2017: A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC)
ASCO 2017: Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)
ASCO 2017: Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma
ASCO 2017: The Dynamic Landscape of Renal Cell Carcinoma Biomarkers: Can We Predict Prognosis, Treatment Response, and Outcome?
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free